GlassScriptPhysician profile
Robert D Malkin
NPI 1689630766
$16,289.71
in general payments reported to CMS, 2019-2025
42 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,832 · 2020: $2,124 · 2021: $2,355 · 2022: $2,334 · 2023: $2,422 · 2024: $2,464 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,643.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,946.98 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,395.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,333.20 | 2019-2025 | |
| Amgen INC. | $1,247.80 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,238.04 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $911.10 | 2019-2025 | Amvuttra, Onpattro |
| Amarin Pharma, INC. | $905.66 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $788.51 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $702.67 | 2019-2024 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $672.69 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $668.84 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $567.19 | 2020-2025 | Nexletol |
| Abbott Laboratories | $450.25 | 2019-2023 | Cardiomems |
| Akcea Therapeutics, INC. | $408.85 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $306.01 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $270.86 | 2024 | Arcalyst |
| Novo Nordisk INC | $270.30 | 2024-2025 | Wegovy, Ozempic |
| Kowa Pharmaceuticals America, INC. | $252.49 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $217.36 | 2022-2023 | Optimizer |
| Scpharmaceuticals INC. | $202.12 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $191.29 | 2024-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $167.79 | 2019-2025 | Evkeeza |
| Philips North America LLC | $165.87 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Kiniksa Pharmaceuticals, LTD. | $165.52 | 2023 | Arcalyst |
| Heartflow, INC. | $124.43 | 2022-2024 | Ffrct |
| Lexicon Pharmaceuticals, INC. | $110.58 | 2023-2024 | Inpefa |
| Vifor Pharma, INC. | $89.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.05 | 2025 | |
| Lundbeck LLC | $66.46 | 2019-2020 | |
| Boston Scientific Corporation | $48.77 | 2022-2023 | Watchman Access System |
| Medtronic, INC. | $47.58 | 2023 | Hawkone |
| Lilly USA, LLC | $41.21 | 2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $32.99 | 2019-2021 | |
| Cvrx, INC. | $32.60 | 2023 | Barostim Neo System |
| Bardy Diagnostics, INC. | $28.87 | 2019-2020 | |
| Sobi, INC | $27.23 | 2021 | |
| Bridgebio Pharma, INC. | $25.21 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $24.85 | 2025 | Shingrix |
| Allergan, INC. | $19.20 | 2019 | |
| Portola Pharmaceuticals, LLC | $17.98 | 2019 | |
| Biotronik INC. | $16.01 | 2022 | |
| Medtronic Vascular, INC. | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Malkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.